Skip to content
10-Q

Quarterly Report

COLUCID PHARMACEUTICALS, INC.

0001564590-16-028478

← back to feed
Filed
Nov 9, 2016 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2016 · Nov 8, 2016 19.25M sh
Cash And Equivalents Q3 2016 · Sep 30, 2016 $83.54M
Cash And Equivalents Q3 2016 · Jun 30, 2016 $83.54M
Cash And Equivalents Q3 2016 · Dec 31, 2015 $27.98M
Cash And Equivalents Q3 2016 · Jun 30, 2015 $36.02M
Cash And Equivalents restated Q3 2016 · Dec 31, 2014 $204K
Stockholders Equity Q3 2016 · Sep 30, 2016 $90.54M
Stockholders Equity Q3 2016 · Dec 31, 2015 $58.41M
Current Liabilities Q3 2016 · Sep 30, 2016 $8.93M
Current Liabilities Q3 2016 · Dec 31, 2015 $5.43M
Total Liabilities Q3 2016 · Sep 30, 2016 $10.43M
Total Liabilities Q3 2016 · Dec 31, 2015 $6.93M
Current Assets Q3 2016 · Sep 30, 2016 $100.95M
Current Assets Q3 2016 · Dec 31, 2015 $65.32M
Total Assets Q3 2016 · Sep 30, 2016 $100.97M
Total Assets Q3 2016 · Dec 31, 2015 $65.34M
Sga Expense Q3 2016 · Sep 30, 2016 $2.21M
Sga Expense Q3 2016 · Sep 30, 2016 $6.49M
Sga Expense restated Q3 2016 · Sep 30, 2015 $3.22M
Sga Expense restated Q3 2016 · Sep 30, 2015 $6.05M
Rd Expense Q3 2016 · Sep 30, 2016 $10.51M
Rd Expense Q3 2016 · Sep 30, 2016 $35.71M
Rd Expense restated Q3 2016 · Sep 30, 2015 $5.78M
Rd Expense restated Q3 2016 · Sep 30, 2015 $13.53M
Net Income Q3 2016 · Sep 30, 2016 −$12.66M
Net Income Q3 2016 · Sep 30, 2016 −$41.99M
Net Income restated Q3 2016 · Sep 30, 2015 −$8.95M
Net Income restated Q3 2016 · Sep 30, 2015 −$19.51M
Operating Income Q3 2016 · Sep 30, 2016 −$12.72M
Operating Income Q3 2016 · Sep 30, 2016 −$42.2M
Operating Income restated Q3 2016 · Sep 30, 2015 −$9M
Operating Income restated Q3 2016 · Sep 30, 2015 −$19.58M